www.fdanews.com/articles/82761-roche-and-biocryst-collaborate-on-clinical-compound-bcx-4208-for-transplantation
ROCHE AND BIOCRYST COLLABORATE ON CLINICAL COMPOUND BCX-4208 FOR TRANSPLANTATION
November 30, 2005
Roche and BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced an exclusive license to develop and commercialize BioCryst's phase I compound, BCX-4208, for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases. BCX-4208 is believed to have a potent ability to modulate T-cell activity. T-cells help the body determine when to initiate immune responses and when to accept or reject newly transplanted organs. By specifically modulating T-cell activity, BCX-4208 may offer transplant and autoimmune patients a more efficacious and tolerable treatment option.